ImClone Tussles With Another Partner, Merck KGaA
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck KGaA seeks more than $18 million in damages, alleging ImClone licensed rights to Erbitux patents it did not own.
You may also be interested in...
Pharma Thriller: ImClone’s Secret Suitor Remains Cloaked In Mystery
Eli Lilly is rumored to be the admirer, offering $70 per share to outbid rival Bristol-Myers Squibb.
Devilish Details: Icahn Looks To Boost Bristol/ImClone Offer
Pity Carl Icahn. The biotech industry's best-known activist shareholder and chairman of ImClone saw the value of his holdings plummet following the Food and Drug Administration's 2001 rejection of the company's lead cancer drug, the EGFR inhibitor Erbitux (cetuximab), and the succeeding insider-trading scandal that sent CEO Sam Waksal to jail
ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute
Each company will pay Israel’s Yeda $60 million, but ImClone also gains license for a patent critical to the production of cetuximab.